Stock of Sarepta Therapeutics, Inc. (SRPT) opened today at $51.280 and are currently trading at $54.140 x 300. More than 1,227,337 shares have exchanged hands compared to an average daily volume of 2,115,790 shares. At the current pps, the market capitalization stands at 3.46B. Analyst are currently predicting a target of $69.24 for Sarepta Therapeutics, Inc.

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. Sarepta Therapeutics, Inc. (SRPT) currently has a Beta value of 1.99. Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent.

Next, let’s take a look at Sarepta Therapeutics, Inc current P/E ratio. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at Sarepta Therapeutics, Inc beta and P/E ratio, the EPS cannot be ignored. Sarepta Therapeutics, Inc EPS for the trailing twelve months was -2.339. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. Sarepta Therapeutics, Inc is estimated to release its next earnings report on Oct 25, 2017 – Oct 30, 2017. It would be interesting to see how the earnings fair out considering the recent developments.

 

Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program

Sarepta Therapeutics and Nationwide Children’s Hospital Announce U.S. Food and Drug Administration (FDA) Clearance of the IND Application for the GALGT2 Gene Therapy Program — Nationwide Children’s Hospital is on track to initiate a Phase 1/2a clinical trial in individuals with Duchenne muscular dystrophy (DMD) by year-end 2017 —

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE